医药导报2024，Vol.43Issue(9)：1457-1460,4.DOI:10.3870/j.issn.1004-0781.2024.09.017
血液透析中心静脉导管封管液——DEFENCATH®
DEFENCATH ®:Hemodialysis Center Venous Catheter Lock Solution
刘红淼 1赵中华 1刘欢 1赵方亮 2李艳玲2
作者信息
- 1. 河北医科大学第一医院药剂科,石家庄 050031
- 2. 石药集团中奇制药技术(石家庄)有限公司药理中心,石家庄 050051
- 折叠
摘要
Abstract
DEFENCATH®(taurolidine/heparin)is the first hemodialysis central venous catheter lock solution approved by the FDA.Taurolidine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacterium and fungal species and anti-endotoxin and anti-exotoxin activities.Moreover,microbial resistance has not been observed,and the safety is good.Low-dose heparin is effective in anticoagulation and has a low risk of bleeding,and the two complement each other,clinical studies have reported that the catheter lock solution(CLS)effectively reduces the incidence of catheter-related blood stream infection(CRBSI),with good safety and significant clinical value.It will bring benefits to renal failure patients undergoing maintenance hemodialysis.关键词
DEFENCATH®/牛磺罗定/肝素/导管相关血流感染/封管液/血液透析Key words
DEFENCATH®/Taurolidine/Heparin/Catheter-related blood stream infeation/Catheter lock solution/Hemodialysis分类
医药卫生引用本文复制引用
刘红淼,赵中华,刘欢,赵方亮,李艳玲..血液透析中心静脉导管封管液——DEFENCATH®[J].医药导报,2024,43(9):1457-1460,4.
